Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
Celgene Inc.
Indication:
Splenomegaly and/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib
Last updated:
May 13, 2022
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Last updated:
May 10, 2022
Status:
Concluded with an LOI
Manufacturer:
Teva Canada Ltd.
Indication:
Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Last updated:
May 10, 2022
Status:
Negotiations were not pursued
Manufacturer:
Medison Pharma Canada Inc.
Indication:
Chronic Immune Thrombocytopenia
Last updated:
May 9, 2022
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Multiple Myeloma (including relapsed)
Last updated:
May 9, 2022
Opsynvi (macitentan and tadalafil)
Status:
Concluded without agreement
Manufacturer:
Janssen Inc.
Indication:
Pulmonary Arterial Hypertension
Last updated:
May 9, 2022
Status:
Negotiations were not pursued
Manufacturer:
LEO Pharma Inc.
Indication:
Atopic dermatitis
Last updated:
May 3, 2022
Status:
Negotiations were not pursued
Manufacturer:
Pendopharm, a division of Pharmascience Inc.
Indication:
Atherothrombotic Events in Coronary Artery Disease
Last updated:
May 3, 2022
Vyxeos (daunorubicin and cytarabine)
Status:
Concluded with an LOI
Manufacturer:
Jazz Pharmaceuticals Canada Inc.
Indication:
Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) or newly diagnosed therapy-related acute myeloid leukaemia (t-AML) , in adults
Last updated:
April 27, 2022
Status:
Concluded with an LOI
Manufacturer:
HLS Therapeutics Inc.
Indication:
Ischemic events in statin-treated patients
Last updated:
April 25, 2022